Advertisement

Update of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

  • Gerald L. AndrioleEmail author
Chapter
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 202)

Abstract

The prostate portion of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial began in the early 1990s to assess the ability of annual PSA and DRE to reduce prostate cancer specific mortality in men aged 55–74. Approximately 80,000 men have been randomized and followed for a minimum of 13 years. Thus far, annual screening in this study has not been associated with a reduction of prostate cancer specific mortality. The potential explanations for this finding are reviewed.

Keywords

Prostate, Lung, Colorectal And Ovarian (PLCO) Prostatic Portion Prostate Cancer-specific Mortality PLCO Trial Healthy Volunteer Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O’Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hsing AW, Izmirlian G, Pinsky PF, Kramer BS, Miller AB, Gohagan JK, Prorok PC; for the PLCO Project Team (2012) Prostate cancer screening in the randomized prostate, Lung, colorectal and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 104(2):125–132. Epub 2012 Jan 6 PMID:22228146Google Scholar
  2. Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O’Brien B, Clapp GS, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD; for the PLCO Project Team (2009) Mortality results from a prostate-cancer screening trial. NEJM 360:1310–1319Google Scholar
  3. Grubb, R.L., Pinksy, P.F., Greenlee, R.T., Izmirlian, G., Miller, A.B., Hickey, T.P., Riley, T.L., Mabie, J.E., Levin, D.L., Chia, D., Kramer, B.S., Reding, D.J., Church, T.R., Yokochi, L.A., Kvale, P.A., Weissfeld, J.L., Urban, D.A., Buys, S.S., Gelmann, E.P., Ragard, L.R., Crawford, E.D., Prorok, P.C., Gohagan, J.K., Berg, C.D., Andriole, G.L; for the PLCO Project Team (2008) Prostate cancer screening in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU 102:1524–1530Google Scholar
  4. Pinsky PF, Miller A, Kramer BS, Church T, Reding D, Prorok P, Gelmann E, Schoen RE, Buys S, Hayes RB, Berg CD (2007) Evidence of a healthy volunteer effect in the prostate lung, colorectal and ovarian cancer screening trial. Am J Epidemiol 165(8):874–881PubMedCrossRefGoogle Scholar
  5. Pinsky PF, Black A, Kramer BS, Miller A, Prorok PC, Berg C (2010) Assessing contamination and compliance in the prostate component of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Clin Trials 7(4):303–311PubMedCrossRefGoogle Scholar
  6. Pinsky PF, Black A, Parnes HL, Grubb R, Crawford ED, Miller A, Reding D, Andriole GL (2012) Prostate cancer specific survival in the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. Cancer Epidemiol 36(6):e401–e406 doi:  10.1016/j.canep.2012.08.008. Epub 2012 Sep 19
  7. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Sharifi R, Blank W, Pandya P, Andriole GL, Culkin D, Wheeler T (2012) Prostate cancer intervention versus observation trial (PIVOT) study group. N Engl J Med 367(3):203–213. doi:  10.1056/NEJMoa1113162. Erratum in: N Engl J Med. 2012 Aug 9; 367(6):582Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Division of Urologic SurgeryWashington University in Saint LouisSt. LouisUSA

Personalised recommendations